Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Gains from Sales and Divestitures (2019 - 2023)

Korro Bio (KRRO) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $1.6 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Gains from Sales and Divestitures rose 195.61% year-over-year to $1.6 million, compared with a TTM value of $1.6 million through Sep 2023, up 195.61%, and an annual FY2022 reading of $551450.0, up 59323.49% over the prior year.
  • Gains from Sales and Divestitures was $1.6 million for Q3 2023 at Korro Bio, up from $673900.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.6 million in Q3 2023 and bottomed at $464.0 in Q3 2020.
  • Average Gains from Sales and Divestitures over 4 years is $298150.3, with a median of $67273.0 recorded in 2020.
  • The sharpest move saw Gains from Sales and Divestitures plummeted 99.28% in 2021, then surged 66839.66% in 2022.
  • Year by year, Gains from Sales and Divestitures stood at $67273.0 in 2020, then plummeted by 98.62% to $928.0 in 2021, then surged by 59323.49% to $551450.0 in 2022, then skyrocketed by 195.61% to $1.6 million in 2023.
  • Business Quant data shows Gains from Sales and Divestitures for KRRO at $1.6 million in Q3 2023, $673900.0 in Q2 2023, and $306775.0 in Q1 2023.